- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01264445
Safety and Immunogenicity Study of 2 Investigational Preventive HIV Vaccines
A Phase I Double-blinded, Placebo-controlled, Randomized Trial in HIV-uninfected, Healthy Adult Volunteers to Evaluate the Safety and Immunogenicity of an Adjuvanted GSK HIV Vaccine Administered With Ad35-GRIN Investigational Vaccine
Study Overview
Status
Conditions
Intervention / Treatment
- Biological: Adjuvanted GSK investigational HIV vaccine formulation 1
- Biological: Ad35 investigational HIV vaccine
- Biological: Ad35 investigational HIV vaccine
- Biological: Ad35 investigational HIV vaccine
- Biological: Placebo (saline)
- Biological: Adjuvanted GSK investigational HIV vaccine formulation 2
- Biological: Adjuvanted GSK investigational HIV vaccine formulation 2
- Biological: Adjuvanted GSK investigational HIV vaccine formulation 2
Detailed Description
Volunteers will be screened up to 42 days before vaccination (up to 90 days for Ad35 neutralizing antibody) and will be followed for 12 months after the last vaccination (16 months total participation).
It is estimated that it will take approximately 5 months to complete enrolment.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy males and females, as assessed by a medical history, physical exam, and laboratory tests
- At least 18 years of age on the day of screening and has not reached his/her 41st birthday on the day of first vaccination
- Willing to comply with the requirements of the protocol and available for follow-up for the planned duration of the study (screening plus 16 months)
- In the opinion of the Principal Investigator or designee and based on Assessment of Informed Consent Understanding results, has understood the information provided and potential risks linked to vaccination and participation in the trial. Written informed consent needs to be provided by the volunteer before any study-related procedures are performed
- Willing to undergo HIV testing, risk reduction counselling, receive HIV test results and committed to maintaining low risk behaviour for the trial duration
- If a female of childbearing potential (not menopausal or anatomically sterile), willing to use an effective non-barrier method of contraception (hormonal contraceptive; intra-uterine device), from screening until four months after last vaccination. All female volunteers must be willing to undergo urine pregnancy tests at time points as indicated in the study protocol and must test negative prior to each vaccination.
- If sexually active male (who is not anatomically sterile), willing to use an effective method of contraception (such as consistent condom use) from the day of first vaccination until 4 months after the last vaccination
- Willing to forgo donations of blood or any other tissues during the study and, for those who test HIV positive after vaccination, until the anti-HIV antibody titres become undetectable
Exclusion Criteria:
- Confirmed HIV-1 or HIV-2 infection
- Any clinically relevant abnormality on history or examination including history of immunodeficiency, malignancy or autoimmune disease; use of systemic corticosteroids (<2 weeks use of topical or inhaled steroids is permitted); immunosuppressive, anticancer, anti-tuberculosis or other medications considered significant by the investigator within the previous 6 months
- Any clinically significant acute or chronic medical condition that is considered progressive, or in the opinion of the investigator, makes the volunteer unsuitable for participation in the study
- Detection of Ad35-specific serum neutralizing antibody
- Reported high-risk behaviour for HIV infection within 6 months prior to first vaccination, as defined by the protocol.
- If female, pregnant or planning a pregnancy within 4 months after last vaccination; or lactating
Unstable asthma (e.g. sudden acute attacks occurring without an obvious trigger) or asthma requiring:
- Daily steroid or long acting beta-agonist prevention
- Hospitalization in the last two years
- Bleeding disorder that was diagnosed by a physician e.g., factor deficiency, coagulopathy or platelet disorder that requires special precautions. (A volunteer who states that he or she has easy bruising or bleeding, but does not have a formal diagnosis and has intramuscular (IM) injections and blood draws without any adverse experience is eligible)
- History of splenectomy
- Any abnormal laboratory parameters as defined by the protocol;
- Receipt of live-attenuated vaccine within the previous 60 days (live attenuated flu vaccine within 14 days) or planned receipt within 60 days after vaccination with Investigational Product; or receipt of other vaccine (e.g. pneumococcal), allergy treatment with antigen injections or tuberculin skin test within the previous 14 days or planned receipt within 14 days after vaccination with Investigational Product
- Receipt of blood transfusion or blood-derived products within the previous 6 months
- Participation in another clinical trial of an Investigational Product currently, within the previous 3 months or expected participation during this study
- Prior receipt of another investigational HIV vaccine candidate (note: receipt of an HIV vaccine placebo will not exclude a volunteer from participation if documentation is available and the IAVI Medical Monitor gives approval)
- History of severe local or systemic reactogenicity to vaccines (e.g. anaphylaxis, respiratory difficulty, angioedema)
- History of severe allergic reactions to any substance requiring hospitalization or emergency medical care (e.g. Steven-Johnson syndrome, bronchospasm or hypotension)
- Known sensitivity to sulphite, aspirin or aminoglycoside antibiotics (e.g. amikacin, arbekacin, gentamicin, kanamycin, neomycin, netilmicin, paromomycin, streptomycin, tobramycin, etc)
- Confirmed diagnosis of active hepatitis B (HBsAg), hepatitis C (HCV antibodies), active syphilis or active tuberculosis
- History of severe neurological disorder, seizure or psychiatric disorder (e.g schizophrenia, severe psychosis, bipolar disorder requiring therapy, suicidal attempt or ideation)
- For those volunteers at clinical centres participating in ophthalmic examinations, any clinically significant abnormality found on baseline ophthalmic examination.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group A
Adjuvanted GSK investigational HIV vaccine at Months 0 and 1 followed by Ad35-GRIN investigational HIV vaccine at Month 4.
|
Receive at Months 0 and 1
Receive at Month 0
Receive at Month 4
Receive at Months 0, 1, and 4
(Vaccine:Placebo=28:7) Groups A, B, C, and D will all have a placebo comparator component (7 volunteers will receive placebo in each group at the specified months.)
|
Experimental: Group B
Adjuvanted GSK investigational HIV vaccine at Months 0 and 1 followed by Ad35-GRIN investigational HIV vaccine at Month 4.
|
Receive at Month 0
Receive at Month 4
Receive at Months 0, 1, and 4
(Vaccine:Placebo=28:7) Groups A, B, C, and D will all have a placebo comparator component (7 volunteers will receive placebo in each group at the specified months.)
Receive at Months 0 and 1
Receive at Months 3 and 4
Receive at Months 0, 1, and 4
|
Experimental: Group C
Ad35-GRIN investigational HIV vaccine at Month 0 followed by Adjuvanted GSK investigational HIV vaccine at Months 3 and 4.
|
Receive at Month 0
Receive at Month 4
Receive at Months 0, 1, and 4
(Vaccine:Placebo=28:7) Groups A, B, C, and D will all have a placebo comparator component (7 volunteers will receive placebo in each group at the specified months.)
Receive at Months 0 and 1
Receive at Months 3 and 4
Receive at Months 0, 1, and 4
|
Experimental: Group D
Adjuvanted GSK investigational HIV vaccine and Ad35-GRIN investigational HIV vaccine co-administered (simultaneous administration with separate injections)at Months 0, 1, and 4.
|
Receive at Month 0
Receive at Month 4
Receive at Months 0, 1, and 4
(Vaccine:Placebo=28:7) Groups A, B, C, and D will all have a placebo comparator component (7 volunteers will receive placebo in each group at the specified months.)
Receive at Months 0 and 1
Receive at Months 3 and 4
Receive at Months 0, 1, and 4
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety of an adjuvanted HIV protein vaccine in prime-boost combinations with AD35-GRIN or coadministered with AD35-GRIN
Time Frame: 16 months
|
Safety of an adjuvanted (dose escalation for adjvans) HIV protein vaccine given as prime or boost in combination with Ad35-GRIN or co-administered with Ad35-GRIN
|
16 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Immunogenicity of an adjuvanted HIV protein vaccine given in different prime-boost regimens with Ad35-GRIN or coadminisitered with Ad35-GRIN
Time Frame: 16 months
|
16 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Gloria S Omosa-Manyonyi, MBChB,DPH,DLSHTM, MSc., Kenya AIDS Vaccine Initiative
- Principal Investigator: Juliet Mpendo, MBChB, MPH, Uganda Virus Research Institute-IAVI
- Principal Investigator: Eugene Ruzagira, MBChB MPH, Medical Research Council-UVRI Uganda Research Unit on AIDS
- Principal Investigator: Elwyn Chomba, BSc, MBChB, DCH, MRCP, Zambia-Emory HIV Research Project
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- HIV Infections
- Physiological Effects of Drugs
- Immunologic Factors
- Vaccines
Other Study ID Numbers
- IAVI B002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on Adjuvanted GSK investigational HIV vaccine formulation 1
-
GlaxoSmithKlineCompletedTuberculosisPhilippines
-
GlaxoSmithKlineCompletedInfluenzaUnited States
-
Sanofi Pasteur, a Sanofi CompanyCompletedTetanus Immunisation (Healthy Volunteers) | Diphtheria Immunisation (Healthy Volunteers) | Pertussis Immunisation (Healthy Volunteers)Canada
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineAerasCompleted
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineActive, not recruitingHerpes SimplexGermany, United States, Belgium, Canada, Spain, United Kingdom, Estonia, Australia